Major pharma company to make significant investment in the UK

28 Nov 2017

MSD's announcement to establish UK Discovery Centre in London an 'endorsement' of the government's Industry Strategy.

MSD (Merck and Co.) is set to establish a state-of-the-art life sciences discovery research facility in London, focussed on early bioscience discovery and entrepreneurial innovation.

Major pharma company to make significant investment in the UK

The new UK Discovery Centre is anticipated to create 150 new research roles with the aim of attracting the brightest and best research scientists to work in London. The new site will accommodate approximately 800 additional staff for the UK domestic market and other European clinical functions currently based in MSD in the UK’s Hoddesdon headquarters.

The company is currently evaluating several potential locations in the London region with a target date of 2020 for operational readiness. In the meantime, MSD plans to establish a small temporary research facility in the area and is actively recruiting for suitably qualified scientific talent.

The proposed investment is in line with MSD Research Laboratories’ continued pursuit of new innovative scientific discovery and collaboration and follows similar investments in new biomedical centres in the San Francisco Bay Area and Cambridge Massachusetts. MSD believes that locating a research facility in London will expand MSD’s opportunity to engage with leading researchers in the UK and Europe.

“Strong discovery capabilities and the pursuit of scientific excellence are foundational to MSD’s mission to save and improve lives around the world,” said Dr Roger M. Perlmutter, president, MSD Research Laboratories. “This new London location will enable us to build on our proud legacy of invention and be an important contributor to the vibrant and rapidly growing London life sciences community while providing access for more collaborations within the European life science ecosystem.”

“We believe London to be a unique bioscience centre of excellence and a key component of the established golden triangle for academic science of London-Oxford-Cambridge,” said Louise Houson, managing director, MSD in the UK and Ireland. “This investment presents a major opportunity for us to work in collaboration with the UK Government to build on the forward-thinking and ambitious Industrial Strategy White Paper published by the Government today.”

It is intended that the UK Discovery Centre will become the location for MSD’s UK HQ, making the central London site a unique location within the UK pharmaceutical sector.

This landmark investment comes as a huge vote of confidence in the UK government’s approach to industrial strategy. Announcing the investment, Business Secretary Greg Clark said: "Our life sciences sector is one of the UK’s fastest developing industries, with a turnover in excess of £64 billion, employing 233,000 across the UK."

He added: "MSD’s commitment, and the wider Sector Deal investment we have secured, proves the process outlined in the Industrial Strategy can give companies the confidence and direction they need to invest in the UK. It will ensure Britain continues to be at the forefront of innovation and represents a huge vote of confidence in our Industrial Strategy."

Read More

Related tags

Top Stories Market News

Related news

EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Global pharma set for strong year

Global pharma set for strong year

23 Oct 2018

Eight of the top ten pharma nations reporting improving market conditions.

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Moulds & Tooling: A European success story

Moulds & Tooling: A European success story

19 Sep 2018

While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more